Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bosentan in the Treatment of Giant Cell Arteritis
NCT06957002Phase 2Not yet recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jun 2026
- Primary completion
- Jun 2029
- Modality
- Nucleic Acid-Directed Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of bosentan in giant cell arteritis (GCA), sponsored by Assistance publique - Hôpitaux de Paris. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
bosentan
03
Conditions
giant cell arteritis (GCA)
Beyond the preview
Go deeper on NCT06957002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06957002.